Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 12/2009

01.12.2009 | Translational Research and Biomarkers

RGS16 Is a Marker for Prognosis in Colorectal Cancer

verfasst von: Norikatsu Miyoshi, MD, Hideshi Ishii, MD, PhD, Mitsugu Sekimoto, MD, PhD, Yuichiro Doki, MD, PhD, Masaki Mori, MD, PhD, FACS

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

The RGS family, comprising 22 homologues of proteins, plays a role in cellular proliferation, differentiation, membrane trafficking, and embryonic development through the involvement of the mitogen-activated protein kinase signaling pathway.

Methods

In order to demonstrate the importance of RGS16 expression for the prediction of prognosis of colorectal cancer (CRC), we analyzed RGS16 gene expression in 22 human gastrointestinal cell lines and 124 paired cases of CRC and noncancerous regions.

Results

RGS16 was expressed in 17 human gastrointestinal cancer cell lines examined in this study. RGS16 expression was higher in colorectal cancer tissue than in corresponding normal tissue (P < 0.001) in messenger RNA (mRNA) and protein levels. Patients in the RGS16 high-expression group showed a poorer overall survival rate than those in the low-expression group (P < 0.001), indicating that high RGS16 expression was an independent prognostic factor.

Conclusion

The present study suggests that RGS16 is useful as a predictive marker for patient prognosis of CRC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Kohno SI, Luo C, Nawa A, Fujimoto Y, Watanabe D, Goshima F, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.CrossRefPubMed
2.
Hermsen M, Postma C, Baak J, Weiss M, Rapallo A, Sciutto A, et al. Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology. 2002;123:1109–19.CrossRefPubMed
3.
Leslie A, Pratt NR, Gillespie K, Sales M, Kernohan NM, Smith G, et al. Mutations of APC, K-ras, and p53 are associated with specific chromosomal aberrations in colorectal adenocarcinomas. Cancer Res. 2003;63:4656–61.PubMed
4.
Tsarouha H, Pandis N, Bardi G, Teixeira MR, Andersen JA, Heim S. Karyotypic evolution in breast carcinomas with i(1)(q10) and der(1;16)(q10;p10) as the primary chromosome abnormality. Cancer Genet Cytogenet. 1999;113:156–61.CrossRefPubMed
5.
Orsetti B, Nugoli M, Cervera N, Lasorsa L, Chuchana P, Rouge C. Genetic profiling of chromosome 1 in breast cancer: mapping of regions of gains and losses and identification of candidate genes on 1q. Br J Cancer. 2006;95:1439–47.CrossRefPubMed
6.
Stange DE, Radlwimmer B, Schubert F, Traub F, Pich A, Toedt G. et al. High-resolution genomic profiling reveals association of chromosomal aberrations on 1q and 16p with histologic and genetic subgroups of invasive breast cancer. Clin Cancer Res. 2006;12:345–52.CrossRefPubMed
7.
Wiechec E, Overgaard J, Hansen LL. A fragile site within the HPC1 region at 1q25.3 affecting RGS16, RGSL1, and RGSL2 in human breast carcinomas. Genes Chromosomes Cancer. 2008;47:766–80.CrossRefPubMed
8.
Tomlinson GE, Douglass EC, Pollock BH, Finegold MJ, Schneider NR. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer. 2005;44:177–84.CrossRefPubMed
9.
Thompson FH, Emerson J, Olson S, Weinstein R, Leavitt SA, Leong SP, et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet. 1995;83:93–104.CrossRefPubMed
10.
Kullendorff CM, Soller M, Wiebe T, Mertens F. Cytogenetic findings and clinical course in a consecutive series of Wilms tumors. Cancer Genet Cytogenet. 2003;140:82–7.CrossRefPubMed
11.
Pandis N, Jin Y, Gorunova L, Petersson C, Bardi G, Idvall I, et al. Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotypic subgroups. Genes Chromosomes Cancer. 1995;12:173–85.CrossRefPubMed
12.
Parada LA, Hallen M, Tranberg KG, Hagerstrand I, Bondeson L, Mitelman F, et al. Frequent rearrangements of chromosomes 1, 7, and 8 in primary liver cancer. Genes Chromosomes Cancer. 1998;23:26–35.CrossRefPubMed
13.
Gorunova L, Hoglund M, Andren-Sandberg A, Dawiskiba S, Jin Y, Mitelman F, et al. Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes Cancer. 1998;23:81–99.CrossRefPubMed
14.
Leung TH, Wong N, Lai PB, Chan A, To KF, Liew CT, et al. Identification of four distinct regions of allelic imbalances on chromosome 1 by the combined comparative genomic hybridization and microsatellite analysis on hepatocellular carcinoma. Mod Pathol. 2002;15:1213–20.CrossRefPubMed
15.
Davidsson J, Andersson A, Paulsson K, Heidenblad M, Isaksson M, Borg A, et al. Tiling resolution array comparative genomic hybridization, expression and methylation analyses of dup(1q) in Burkitt lymphomas and pediatric high hyperdiploid acute lymphoblastic leukemias reveal clustered near-centromeric breakpoints and overexpression of genes in 1q22-32.3. Hum Mol Genet. 2007;16:2215–25.CrossRefPubMed
16.
Alers JC, Rochat J, Krijtenburg PJ, Hop WC, Kranse R, Rosenberg C, et al. Identification of genetic markers for prostatic cancer progression. Lab Invest. 2000;80:931–42.PubMed
17.
Nishimura T, Nishida N, Itoh T, Komeda T, Fukuda Y, Ikai I, et al. Discrete breakpoint mapping and shortest region of overlap of chromosome arm 1q gain and 1p loss in human hepatocellular carcinoma detected by semiquantitative microsatellite analysis. Genes Chromosomes Cancer. 2005;42:34–43.CrossRefPubMed
18.
Sobin LH, Witedkind CH. UICC TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997. p. 66–9.
19.
Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–6.PubMed
20.
Mori M, Staniunas RJ, Barnard GF, Jessup JM, Steele GD Jr, Chen LB. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105:820–6.PubMed
21.
Chen C, Zheng B, Han J, Lin SC. Characterization of a novel mammalian RGS protein that binds to Galpha proteins and inhibits pheromone signaling in yeast. J Biol Chem. 1997;272:8679–85.CrossRefPubMed
22.
Chen CK, Wieland T, Simon MI. RGS-r, a retinal specific RGS protein, binds an intermediate conformation of transducin and enhances recycling. Proc Natl Acad Sci USA. 1996;93:12885–9.CrossRefPubMed
23.
Snow BE, Antonio L, Suggs S, Siderovski DP. Cloning of a retinally abundant regulator of G-protein signaling (RGS-r/RGS16): genomic structure and chromosomal localization of the human gene. Gene. 1998;206:247–53.CrossRefPubMed
24.
Mittmann C, Chung CH, Hoppner G, Michalek C, Nose M, Schuler C, et al. Expression of ten RGS proteins in human myocardium: functional characterization of an upregulation of RGS4 in heart failure. Cardiovasc Res. 2002;55:778–86.CrossRefPubMed
25.
Ogier-Denis E, Pattingre S, El Benna J, Codogno P. Erk1/2-dependent phosphorylation of Galpha-interacting protein stimulates its GTPase accelerating activity and autophagy in human colon cancer cells. J Biol Chem. 2000;275:39090–5.CrossRefPubMed
26.
Derrien A, Zheng B, Osterhout JL, Ma YC, Milligan G, Farquhar MG, et al. Src-mediated RGS16 tyrosine phosphorylation promotes RGS16 stability. J Biol Chem. 2003;278:16107–16.CrossRefPubMed
27.
Andre T, Quinaux E, Louvet C, Colin P, Gamelin E, Bouche O, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.CrossRefPubMed
28.
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–310.CrossRefPubMed
29.
Kornmann M, Formentini A, Ette C, Henne-Bruns D, Kron M, Sander S, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.PubMed
30.
Bathe OF, Dowden S, Sutherland F, Dixon E, Butts C, Bigam D, et al. Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 2004;4:32.CrossRefPubMed
31.
Lacy AM, Garcia-Valdecasas JC, Delgado S, Castells A, Taura P, Pique JM, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–9.CrossRefPubMed
32.
Weeks JC, Nelson H, Gelber S, Sargent D, Schroeder G. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.CrossRefPubMed
33.
Clinical Outcomes of Surgical Therapy Study Group. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–9.
34.
Jayne DG, Guillou PJ, Thorpe H, Quirke P, Copeland J, Smith AM, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.CrossRefPubMed
35.
Liu T, Bohlken A, Kuljaca S, Lee M, Nguyen T, Smith S, et al. The retinoid anticancer signal: mechanisms of target gene regulation. Br J Cancer. 2005;93:310–8.CrossRefPubMed
36.
Ross EM, Wilkie TM. GTPase-activating proteins for heterotrimeric G proteins: regulators of G protein signaling (RGS) and RGS-like proteins. Annu Rev Biochem. 2000;69:795–827.CrossRefPubMed
37.
Hu Y, Xing J, Chen L, Guo X, Du Y, Zhao C, et al. RGS22, A Novel Testis-Specific Regulator of G-protein Signaling Involved in Human and Mouse Spermiogenesis along with GNA12/13 Subunits. Biol Reprod. 2008;79:1021–9.CrossRefPubMed
38.
Dohlman HG, Thorner J. RGS proteins and signaling by heterotrimeric G proteins. J Biol Chem. 1997;272:3871–4.CrossRefPubMed
39.
Berman DM, Gilman AG. Mammalian RGS proteins: barbarians at the gate. J Biol Chem. 1998;273:1269–72.CrossRefPubMed
40.
Cavalli A, Druey KM, Milligan G. The regulator of G protein signaling RGS4 selectively enhances alpha 2A-adreoreceptor stimulation of the GTPase activity of Go1alpha and Gi2alpha. J Biol Chem. 2000;275:23693–9.CrossRefPubMed
41.
Druey KM, Blumer KJ, Kang VH, Kehrl JH. Inhibition of G-protein-mediated MAP kinase activation by a new mammalian gene family. Nature. 1996;379:742–6.CrossRefPubMed
42.
De Vries L, Gist Farquhar M. RGS proteins: more than just GAPs for heterotrimeric G proteins. Trends Cell Biol. 1999;9:138–44.CrossRefPubMed
43.
Hepler JR. Emerging roles for RGS proteins in cell signalling. Trends Pharmacol Sci. 1999;20:376–82.CrossRefPubMed
44.
Chen C, Wang H, Fong CW, Lin SC. Multiple phosphorylation sites in RGS16 differentially modulate its GAP activity. FEBS Lett. 2001;504:16–22.CrossRefPubMed
45.
Buckbinder L, Velasco-Miguel S, Chen Y, Xu N, Talbott R, Gelbert L, et al. The p53 tumor suppressor targets a novel regulator of G protein signaling. Proc Natl Acad Sci USA. 1997;94:7868–72.CrossRefPubMed
Metadaten
Titel
RGS16 Is a Marker for Prognosis in Colorectal Cancer
verfasst von
Norikatsu Miyoshi, MD
Hideshi Ishii, MD, PhD
Mitsugu Sekimoto, MD, PhD
Yuichiro Doki, MD, PhD
Masaki Mori, MD, PhD, FACS
Publikationsdatum
01.12.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0690-3

Weitere Artikel der Ausgabe 12/2009

Annals of Surgical Oncology 12/2009 Zur Ausgabe

Thoracic Oncology

Ambulatory Intercostal Drainage for the Management of Malignant Pleural Effusion: A Single Center Experience

Breast Oncology

Ratio Between Positive Lymph Nodes and Total Excised Axillary Lymph Nodes as an Independent Prognostic Factor for Overall Survival in Patients with Nonmetastatic Lymph Node-Positive Breast Cancer

Hepatobiliary Tumors

Validation of Prognostic Scoring Systems for Patients Undergoing Resection of Colorectal Cancer Liver Metastases

Endocrine Tumors

Utility of Intraoperative PTH for Primary Hyperparathyroidism Due to Multigland Disease

Pancreatic Tumors

Survival Data Justifies Resection for Pancreatic Metastases

Bone and Soft Tissue Sarcomas

Treatment and Outcomes in Adult Patients with Primary Cardiac Sarcoma: The British Columbia Cancer Agency Experience

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.